Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00619957 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis
A Phase 3 study, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 3
- Development phase
- 285
- Enrollment target
NCT00619957 is a Phase 3 study that has completed, run by Warner Chilcott. The registered enrollment target is 285 participants.
The verdict
NCT00619957, a Phase 3 study, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 285 participants
- Enrollment target
Study Summary
Two year study to determine the safety and efficacy of weekly 35 mg Risedronate doses in men with osteoporosis followed by a two year follow-up study.
Interventions
- DRUG Placebo tablet
- DRUG Risedronate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2002-06 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00619957
The ClinicalTrials.gov registry entry for NCT00619957 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 285 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo tablet is the first listed.
NCT00619957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00619957 about?
NCT00619957 is a clinical study titled "Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis". Two year study to determine the safety and efficacy of weekly 35 mg Risedronate doses in men with osteoporosis followed by a two year follow-up study.
What is the current status of trial NCT00619957?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 285 participants. The study started on 2002-06. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00619957?
The interventions under investigation include: Placebo tablet (DRUG), Risedronate (DRUG).
Who is sponsoring clinical trial NCT00619957?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.